The firm presented early data for a blood-based approach to screen prostate cancer patients for PSMA, which it believes has ...

As the demand for more accurate and timely diagnostic methods increases, innovations in molecular diagnostics, such as next-generation sequencing (NGS) and liquid biopsy, are gaining traction.

Liu, a medical oncologist and cancer investigator at the Mayo Clinic in Rochester, Minnesota, is one of a growing number of researchers advancing liquid biopsies as tools to understand cancer biology.

related to the emphasis on innovation and rapid growth of liquid biopsy. Guardant is not just innovating but redefining cancer diagnostics with AI-driven genomic and epigenomic sequencing of an ...

Pharus Diagnostics LLC. (PharusDx), an innovator in non-invasive diagnostic tests, today announced a significant step forward in the fight against pancreatic cancer. The company is announcing ...

New data to be presented at AMP 2024 demonstrates best-in-class tissue and blood performance from both DNA and RNA "Until now there has not been an alternative to next-generation sequencing (NGS ...

Nov. 06, 2024 (GLOBE NEWSWIRE) -- Predicine, Inc., a pioneer in the field of liquid biopsy, is pleased to announce ... PredicineCARE™, a next-generation sequencing (NGS) assay, facilitated blood-based ...

Global Refractory Follicular Lymphoma Diagnostics Market Projected to Reach USD 464.47 Million by 2029 Refractory Follicular ...